The 36-month beta value for VRPX is also noteworthy at 0.90. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for VRPX is 7.59M, and at present, short sellers hold a 4.15% of that float. The average trading volume of VRPX on December 04, 2024 was 3.13M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
VRPX) stock’s latest price update
The stock of Virpax Pharmaceuticals Inc (NASDAQ: VRPX) has decreased by -9.50 when compared to last closing price of 0.44.Despite this, the company has seen a loss of -17.81% in its stock price over the last five trading days. businesswire.com reported 2024-11-22 that BERWYN, Pa.–(BUSINESS WIRE)–Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced results from a minipig Dose Range Finding (“DRF”) study for Probudur. Probudur is the company’s long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediate.
VRPX’s Market Performance
Virpax Pharmaceuticals Inc (VRPX) has experienced a -17.81% fall in stock performance for the past week, with a -44.44% drop in the past month, and a -51.30% drop in the past quarter. The volatility ratio for the week is 12.15%, and the volatility levels for the past 30 days are at 17.21% for VRPX. The simple moving average for the past 20 days is -32.42% for VRPX’s stock, with a -75.14% simple moving average for the past 200 days.
VRPX Trading at -35.29% from the 50-Day Moving Average
After a stumble in the market that brought VRPX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.80% of loss for the given period.
Volatility was left at 17.21%, however, over the last 30 days, the volatility rate increased by 12.15%, as shares sank -42.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -42.84% lower at present.
During the last 5 trading sessions, VRPX fell by -17.71%, which changed the moving average for the period of 200-days by -85.37% in comparison to the 20-day moving average, which settled at $0.5837. In addition, Virpax Pharmaceuticals Inc saw -87.68% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for VRPX
The total capital return value is set at 6.52. Equity return is now at value -594.46, with -198.45 for asset returns.
Currently, EBITDA for the company is -15.19 million with net debt to EBITDA at 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.08.
Conclusion
In summary, Virpax Pharmaceuticals Inc (VRPX) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
